Premium
Insights from compassionate use of tocilizumab for COVID‐19 to inform appropriate design of randomised controlled trials
Author(s) -
Baker Emma H.,
Patel Kamal,
Ball Jonathan,
Edwards Sarah,
Harrison Thomas S.,
Kaul Arvind,
Koh Mickey,
Krishna Sanjeev,
Leaver Susannah,
Kumar Vinodh,
Forton Daniel M.
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14466
Subject(s) - tocilizumab , medicine , cytokine release syndrome , ritonavir , cytokine , immunology , immune dysregulation , clinical trial , rheumatoid arthritis , immune system , t cell , viral load , chimeric antigen receptor , antiretroviral therapy , human immunodeficiency virus (hiv)
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom